Vaxzevria (previously COVID-19 Vaccine AstraZeneca) - direct healthcare professional communication (DHPC)

ChAdOx1-SARS-COV-2

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC): Vaxzevria (previously COVID-19 Vaccine AstraZeneca): contraindication in individuals with previous capillary leak syndrome

Dissemination date: 23/06/2021

Key facts

• Medicine name:
  Vaxzevria (previously COVID-19 Vaccine AstraZeneca)
• Active substance:
  ChAdOx1-SARS-COV-2
• Therapeutic area (MeSH):
  COVID-19 virus infection
• Regulatory outcome:
  Variation
• DHPC type:
  Safety signal
• Human ATC codes:
  J07BX03
• Dissemination date:
  23/06/2021